Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Chandler syndrome, the most frequent clinical variant of iridocorneal endothelial (ICE) syndrome, is characterized by very few iris abnormalities but more severe corneal edema and less severe secondary glaucoma than seen in the other two ICE syndrome variants: Cogan-Reese syndrome and essential iris atrophy.
Biomarker and diagnostic research for Chandler syndrome has been reported in the published literature.
12 clinical trials registered, 9 recruiting. Interventions under study include procedural interventions, drug therapy, other interventions, and medical devices. Pipeline includes 2 PHASE2, 5 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07373821](https://clinicaltrials.gov/study/NCT07373821) |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 6:00 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Chandler syndrome
Influence of Supine Positioning on the Outcomes After Descemet Membrane Endothelial Keratoplasty (DMEK) |
NA |
University Hospital Heidelberg |
RECRUITING |
[NCT07024693](https://clinicaltrials.gov/study/NCT07024693) | DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy | PHASE2 | Design Therapeutics, Inc. | RECRUITING |
[NCT04440280](https://clinicaltrials.gov/study/NCT04440280) | Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy | PHASE2 | Massachusetts Eye and Ear Infirmary | RECRUITING |
[NCT07265388](https://clinicaltrials.gov/study/NCT07265388) | SUCCESS Score Validation in Fuchs Dystrophy | — | Instituto Ramón y Cajal de Investigación Sanitaria | RECRUITING |
[NCT06859411](https://clinicaltrials.gov/study/NCT06859411) | Prognosis of Posterior Lamellar Keratoplasty | — | Centre Hospitalier Régional Metz-Thionville | RECRUITING |
106 publications have been identified in PubMed for Chandler syndrome. Kisho has analyzed 47 by research type. Research spans Basic Science / Preclinical (34%), Review / Meta-Analysis (30%), and Case Report / Case Series (11%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 16 | 34% |
Research summaries | 14 | 30% |
Patient case studies | 5 | 11% |
Clinical study results | 5 | 11% |
Disease patterns and progression | 4 | 9% |
Testing and diagnosis research | 2 | 4% |
New treatment approaches | 1 | 2% |
Flockerzi E (2026). [PMID: 41248687](https://pubmed.ncbi.nlm.nih.gov/41248687/). *Klin Monbl Augenheilkd*. [Review / Meta-Analysis]
Nayak D (2026). [PMID: 42061480](https://pubmed.ncbi.nlm.nih.gov/42061480/). *Free Radic Biol Med*. [Basic Science / Preclinical]
Zhang W (2026). [PMID: 41896991](https://pubmed.ncbi.nlm.nih.gov/41896991/). *Biol Sex Differ*. [Basic Science / Preclinical]
Marrugo AG (2026). [PMID: 41915721](https://pubmed.ncbi.nlm.nih.gov/41915721/). *PLOS Digit Health*. [Review / Meta-Analysis]
Sahin EE (2026). [PMID: 41961333](https://pubmed.ncbi.nlm.nih.gov/41961333/). *Int Ophthalmol*. [Clinical Trial Publication]
Holland EJ (2025). [PMID: 40032264](https://pubmed.ncbi.nlm.nih.gov/40032264/). *Cornea*. [Clinical Trial Publication]
Liu S (2025). [PMID: 40478592](https://pubmed.ncbi.nlm.nih.gov/40478592/). *Transl Vis Sci Technol*. [Review / Meta-Analysis]
Parekh M (2025). [PMID: 40629926](https://pubmed.ncbi.nlm.nih.gov/40629926/). *Eur J Ophthalmol*. [Clinical Trial Publication]
Saleki M (2025). [PMID: 40837591](https://pubmed.ncbi.nlm.nih.gov/40837591/). *Ther Adv Ophthalmol*. [Case Report / Case Series]
Gaudenzi D (2025). [PMID: 40525464](https://pubmed.ncbi.nlm.nih.gov/40525464/). *Eur J Ophthalmol*. [Clinical Trial Publication]